Table 2.
Main characteristics of the eligible studies for prognostic meta-analysis.
| Study | Year | Country | Cancer type | Sample type | Gender high/low male (female) | Up-/downregulation | Single/multiple miRNAs | Methods | Cases high/low | Cut-off | Survival | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chen 2014 | 2014 | China | GC | Plasma | NA | Up | Multiple | qRT-PCR | 29/33 | NA | OS | 0.894 (0.391-2.041) |
| Li 2018 | 2018 | China | CoC | Tissue | 20 (18)/20 (40) | Down | Single | qRT-PCR | 38/60 | 97.43 | OS | 0.500 (0.390-0.610) |
| Lian 2016 | 2016 | China | HCC | Tissue | NA | Down | Single | qRT-PCR | 24/71 | NA | OS | 0.267 (0.081-0.887) |
| Mancuso 2016 | 2016 | Italy | SCLC | Tissue | 32 (18) | Up | Multiple | qRT-PCR | 25/25 | 13.59 | OS | 1.330 (0.720-2.450) |
| Tian 2018 | 2018 | China | AML | Serum | 31 (19)/26 (21) | Down | Single | qRT-PCR | 50/47 | NA | OS | 0.490 (0.342-0.758) |
GC: gastric cancer; CoC: colon cancer; SCLC: small-cell lung cancer; HCC: hepatocellular carcinoma; AML: acute myeloid leukemia; high: high miR-192 expression; low: low miR-192 expression; NA: not available; HR: hazard ratio.